NCT03023124已完成2 期
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 6
- 主要终点
- Overall Tumor Response Rate
研究概览
简要总结
Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor
详细描述
Patients with solitary fibrous tumor will be randomized to receive 6 cycles of trabectedin or doxorubicin plus dacarbazine.
In case of progression or unacceptable toxicity while under the experimental treatment prior to the completion of the 6 cycles, the patients will be offered to cross to the other arm (trabectedin arm to doxorubicin plus dacarbazine arm and vice versa).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient or legal representative must be able to read and understand the informed consent form (ICF) and must have been willing to give written informed consent and any locally required authorisation before any study-specific procedures, including screening evaluations, sampling, and analyses.
- •Age ≥18 years
- •Histological centrally and molecularly confirmed diagnosis of solitary fibrous tumor (inclusive of the last available tumor sample)
- •Locally advanced disease (i.e. surgical resection of local disease unfeasible radically, or unaccepted by the patient, or amenable to become less demolitive, or feasible, or easier, after cytoreduction) and/or metastatic disease
- •Measurable or evaluable disease with RECIST
- •Evidence of progression by RECIST during the 6 months before study entry
- •Patients must be cytotoxic chemotherapy naïve (patients treated with neoadjuvant/adjuvant chemotherapy cannot be included) or could have received a previous target agent in front-line setting.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
- •Adequate bone marrow function
- •Adequate organ function
- •Cardiac ejection fraction ≥50% as measured by echocardiogram
- •Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation each cycle of chemotherapy. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study.
- •No history of arterial and/or venous thromboembolic event within the previous 12 months.
排除标准
- •Any prior treatment with cytotoxic chemotherapy
- •>1 line of anticancer targeted agents
- •Previous treatment with any other investigational or not investigational agents within 14 days of first day of study drug dosing
- •Previous treatment with radiation therapy within 14 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents previously administered
- •Previous radiotherapy to 25 % of the bone marrow
- •Major surgery within 4 weeks prior to study entry
- •Other primary malignancy with <5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse
- •Pregnancy or breast feeding
- •Cardiovascular diseases resulting in a New York Heart Association Functional Status >2 (24). Medical history of a myocardial infarction < 6 months prior to initiation of study treatment
- •Medical history of arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within 6 months prior to the initiation of study treatment
- •Known history of human immunodeficiency virus infection
- •Active or chronic hepatitis B or C requiring treatment with antiviral therapy
- •Medical history of hemorrhage or a bleeding event ≥ Grade 3 (NCI-CTCAE v 4.0) within 4 weeks prior to the initiation of study treatment
- •Evidence of any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
- •Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
- •Expected non-compliance to medical regimens
研究组 & 干预措施
Trabectedin
Experimental
trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles
干预措施: Trabectedin (Drug)
Adriamycin and Dacarbazine
Experimental
Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
干预措施: Adriamycin (Drug)
Adriamycin and Dacarbazine
Experimental
Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
干预措施: Dacarbazine (Drug)
结局指标
主要结局
Overall Tumor Response Rate
时间窗: From the date of randomization until the date of first documented progression or date of death from any cause, whichever came first assessed up to 54 weeks.
evaluate the activity of trabectedin and of adriamycin in combination with dacarbazine, according to Response Evaluation Criteria in Solid Tumor (RECIST), version 1.1
次要结局
- Choi Response Rate(week 6, week 12, week 18, then every 12 weeks up to 54 weeks)
- Overall Survival (OS)(From enrollment up to 5 years)
- Progression Free Survival (PFS)(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks)
- Clinical Benefit Rate (CBR)(week 6, week 12, week 18, then every 12 weeks up to 54 weeks)
- Response rate by RECIST after the cross over(week 18, week 24, week 30, week 36 and then every 12 weeks up to 54 weeks)
- Progression Free Survival (PFS) after cross over up to progression according to RECIST, or death(From date of cross over until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks)
- Safety according to Common Terminology Criteria for Adverse Events (CTCAE)(From enrollment every 3 weeks up to 54 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic SarcomaSarcoma MetastaticSarcomaNCT04076579University of Michigan Rogel Cancer Center29
撤回
1 期
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent LeiomyosarcomaLeiomyosarcomaNCT03437070University of Miami
终止
2 期
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STSSarcomaNCT01104298Grupo Espanol de Investigacion en Sarcomas115
已完成
2 期
Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)Carcinosarcoma, OvarianCarcinosarcomas UterineNCT02993705Fondazione Policlinico Universitario Agostino Gemelli IRCCS45
已完成
2 期
Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.Advanced Soft Tissue SarcomaNCT03838744Italian Sarcoma Group130